Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

17 Jun 2022

Abstract excerpt

T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical efficacy and no malignant transformation due to insertional mutagenesis to date. Large-scale production of RVs/LVs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35784280
DOI: 10.3389/fimmu.2022.865424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene EditingPMID 35784280Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

CRISPR/Cas-based CAR-T cells: production and applicationSemantic proximity Read ↗

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T CellsSemantic proximity Read ↗

Non-viral chimeric antigen receptor (CAR) T cells going viralSemantic proximity Read ↗

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art reviewSemantic proximity Read ↗

High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNASemantic proximity Read ↗

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

CAR T-cell Therapy: A New Era in Cancer ImmunotherapySemantic proximity Read ↗

Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cellsSemantic proximity Read ↗

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.